Company Overview
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and meet other administrative requirements; inventory management software to facilitate ordering and inventory control; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female patients. The company was founded in 2012 and is headquartered in Irving, Texas.
Why Investors Should Care
Return on capital employed stands at 56.8%.
Net profit has compounded at 24.9% per year over the last five years.
Trades at a P/E of 5.1, below the sector median of 25.4.
Recent Developments
- Dec 2025 Revenue of $192.22M (-2.5% YoY); net profit $27.05M.
- Trailing 12 Months Year-on-year growth — revenue -8.3%, earnings -83.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 8.4%, profit CAGR 24.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 8.36% |
| 1 Year: | -8.30% |
Compounded Profit Growth
| 5 Years: | 24.90% |
| 1 Year: | -83.80% |
Stock Price Performance
| 1 Year: | -45.79% |
| 6 Months: | -15.12% |
| 3 Months: | +22.35% |
| 1 Month: | -9.88% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)51.24 · Neutral
P/E of 5.09 is below the sector median of 25.41 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Healthy ROCE of 56.8%.
- Profit CAGR of 24.9% over 5 years.
CONS
- Trading 51.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BTMD biote Corp. R2K | 2.19 | 5.09 | $66.43M | 0.00% | 56.77% | -46.20% | 8.36% | 24.90% |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 34.75M | 35.57M | 37.14M | 41.36M | 41.97M | 44.84M | 49.26M | 45.56M | 46.80M | 49.17M | 51.38M | 48.99M | 48.86M | 47.96M | 44.94M |
| Operating Income | -107.88K | 10.26M | 8.98M | 9.76M | -85.60M | 7.82M | 7.88M | 7.67M | 7.60M | 10.43M | 6.23M | 12.18M | 9.69M | 10.77M | 8.27M | 3.17M |
| Net Income | -3.94M | 13.24M | - | 1.17M | -2.61M | 15.00K | -6.80M | -5.14M | 7.53M | -4.16M | -7.09M | 10.70M | 13.72M | 3.19M | 8.19M | 2.28M |
| Diluted EPS | - | - | - | - | -0.34 | 0.00 | -0.39 | -0.25 | 0.24 | -0.12 | -0.21 | 0.33 | 0.37 | 0.10 | 0.22 | 0.06 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 139.40M | 164.96M | 185.36M | 197.19M | 192.22M |
| Operating Income | 34.56M | -60.72M | 28.66M | 31.61M | 35.55M |
| Net Income | 11.11M | -969.00K | 3.32M | 3.16M | 27.05M |
| Diluted EPS | - | -0.12 | 0.13 | 0.09 | 0.74 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jul 2020 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 147.50K | 54.33M | 111.64M | 155.29M | 122.37M | 107.61M |
| Total Equity | 0 | 25.00K | 4.12M | -44.46M | -29.40M | -105.93M | -58.54M |
| Cash & Equivalents | - | 1.59K | 130.36K | 79.23M | 89.00M | 39.34M | 24.12M |
| Long Term Debt | - | - | 31.96M | 112.09M | 106.63M | 101.20M | 95.78M |
| Total Liabilities | - | 122.50K | 50.20M | 169.92M | 191.84M | 224.57M | 158.01M |
| Current Liabilities | - | 122.50K | 17.31M | 18.77M | 22.21M | 51.51M | 44.99M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | 33.72M | -9.16M | 26.88M | 45.24M | 35.19M |
| Investing Cash Flow | -3.81M | -1.84M | -2.71M | -18.80M | -6.86M |
| Financing Cash Flow | -20.34M | 63.46M | -14.38M | -76.08M | -43.55M |
| Capital Expenditure | -1.45M | -333.00K | -359.00K | -6.43M | -5.01M |
| Free Cash Flow | 32.27M | -9.49M | 26.52M | 38.81M | 30.18M |
| Share Buybacks | - | - | - | 5.60M | 3.37M |
| Dividends Paid | 11.40M | 12.89M | 8.69M | 4.74M | 1.73M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | 24.8% | -36.8% | 15.5% | 16.0% | 18.5% |
| Net Margin % | 8.0% | -0.6% | 1.8% | 1.6% | 14.1% |
| ROE % | 269.4% | 2.2% | -11.3% | -3.0% | -46.2% |
| ROCE % | 93.4% | -65.4% | 21.5% | 44.6% | 56.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | 325 Capital Llc | 14.32% | 4.55M | $10.05M |
| 2 | Bandera Partners LLC | 6.51% | 2.07M | $4.56M |
| 3 | Blackrock Inc. | 5.48% | 1.74M | $3.84M |
| 4 | Vanguard Capital Management LLC | 3.51% | 1.11M | $2.46M |
| 5 | Acadian Asset Management. LLC | 2.20% | 697.86K | $1.54M |
| 6 | State Street Corporation | 2.04% | 646.95K | $1.43M |
| 7 | Geode Capital Management, LLC | 1.94% | 615.66K | $1.36M |
| 8 | Dimensional Fund Advisors LP | 1.71% | 543.49K | $1.20M |
| 9 | Globeflex Capital L P | 0.86% | 272.40K | $602.00K |
| 10 | Northern Trust Corporation | 0.85% | 269.11K | $594.74K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BTMD
BTMD Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE8xaTdWTE5pOGRUUlFPbXdZc0ZXYzF6OXBBQndZUWViYUFSd0VSSTE0aGhCUzVIOWdjcDV4d1Z2S0xOQTFKMWR6XzNpZEU1V3FDVGVDakktZjF0UktscVdZcHBOa3I3ckg1blZkRGZPcTNGRG5majNnMGt3?oc=5" target="_blank">BTM…
How The Investment Story For Biote (BTMD) Is Shifting With Reset Expectations And 2026 Guidance - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQRENNN042WlY1bGttdUxmSGRSTXNtR25TYTZHWUdwR0d5YkdDUkNjQU9lTU5kUVdBenQ2dnpOUGJGUGxCRmFaNjBPUVJSS3dPRnR0M3lXbjFmOVJYWmIyREl1N2d1RFQteF9HTlNiZU4wUEZabmRzZ1VLejZXT3hfd1RfdUd6aVhYUjhpSV…
Biote (NASDAQ: BTMD) names interim CEO, appoints Executive Chairman and reaffirms 2026 outlook - Stock Titan
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxNVjdSUkhWRl8tWjZkR2MwZ2k3S1gweGFuV2tXb1gyMnQ2QmpUTTl4cHl5N21zZ1pzUFJmWTlEcmtiMDJwOHZMVVpDZExfdWJneHNoUHBwZ3g4RDZzQWtmZWlXYWE2RmN0S2pfZ3lFUEFUekZ6bEFJeXRyXzdNdXJPMDFMMDNHQzBEUlFSMk…
Biote Corp. (BTMD) Releases Q1 2026 Earnings: Revenue Falls 8.3% While EPS Beats Estimates - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxPX0hYSzQtVURGRmM2dkRYRlRfZ1BTaTRJd2Y3Mkt1TlEwa3FJUHZWWU1rbGNmN3FCUGtjUktGQXFmQlEtM3hNbUNmRzg1VzVYRWRwTS1KSWF5NS1SWWUzQ3B4T29JcFNXYWVlM0drSmVPUGdPSUFzeF9wVXMwZGpxYkQ5Q0Nnd3pvU2V0ej…
biote Corp.'s (NASDAQ:BTMD) latest 10% decline adds to one-year losses, institutional investors may consider drastic measures - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxPSHllM3pCb09POTJLUHNkelJaeDZqbGMtNGlDajJ3RHlpMnR6Z0VUZWdmaF9sNjg5Q0MwY1ktMm0yT2I1Yk1iQVAxSEZPQ3RhZzlEb2VZRmFmRWxpeGZlSzJXR291UTZmaGxUaEhMRzhmcU1oUk5oZmFUcW4xcmY0UVBpd2VXdUFtOU0zWH…
Biote Announces Interim CEO Amid Leadership Transition Plans - The Globe and Mail
<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxPbUdaQnBLSUQ1OHZWcHZKZkxRLWNmYWdhWGZiTXlmX3FJQWdtcEdhczg2a3pmR3A5OE5QSzNzYmc5eHVYVWFVazZsYXdUN1ozY01TQVB6VUpDb1ZBWXVva19qY3k3ajlZXzBKQ18tMVFQZUZITFR6bU1fUFBjTW1WSXZ1S0JQNnhLeUpqNV…
BTMD — Frequently Asked Questions
What is the current share price of biote Corp. (BTMD)?
As of 2026-07-14 21:23 PDT, biote Corp. (BTMD) trades at $2.19 on NasdaqGM. Its 52-week range is $1.30 to $4.55.
What is the market capitalisation of BTMD?
biote Corp. (BTMD) has a market capitalisation of $66.43M on NasdaqGM.
What is the P/E ratio of BTMD?
BTMD trades at a trailing price-to-earnings (P/E) ratio of 5.09. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is -1.31.
What is the return on equity (ROE) of BTMD?
BTMD has a return on equity (ROE) of -46.20%. Its return on capital employed (ROCE) is 56.77%.
Is BTMD a good stock to buy?
This page provides a data-driven analysis of biote Corp. (BTMD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.